Principal Investigator(s):Vidar Wendel-Hansen, MD PhD - Bionor Pharma AS
Objective:To evaluate safety of the vaccination regimens. To evaluate C5-specific humoral immune responses (antibodies), T cell responses, T cell activation markers and other immune markers.
Prevention Option(s):Therapeutic Vaccines
Study Design:Non-randomized, Open label
Arms and Assigned Interventions
DescriptionArm A: Vacc-C5 /GM-CSF. Vacc-C5 with GM-CSF as adjuvant.
Mode of DeliveryIntradermal
Official Code: NCT01627678
Trial Sponsors: Bionor Immuno AS
September 30, 2012
November 30, 2013
Age range: 18 Years ↔ 55 Years
Population:Cisgender Men, Cisgender Women, People Living with HIV